BLEEDnFIRE Therapeutics
1 known investors
BLEEDnFIRE is a Switzerland-based biotechnology company developing RNA-based (siRNA) therapies for bleeding disorders such as von Willebrand disease, Glanzmann thrombasthenia, and hemophilia A. Its lead program is a GalNAc-conjugated siRNA that reduces hepatic Protein S to rebalance coagulation and restore thrombin generation.
BiotechMedical Devices
Investors · 1
Frequently asked questions
- What does BLEEDnFIRE Therapeutics do?
- BLEEDnFIRE is a Switzerland-based biotechnology company developing RNA-based (siRNA) therapies for bleeding disorders such as von Willebrand disease, Glanzmann thrombasthenia, and hemophilia A. Its lead program is a GalNAc-conjugated siRNA that reduces hepatic Protein S to rebalance coagulation and restore thrombin generation.
- Who are BLEEDnFIRE Therapeutics's investors?
- BLEEDnFIRE Therapeutics's investors include Kickfund.